Cargando…

Modelling of a genetically diverse evolution of Systemic Mastocytosis with Chronic Myelomonocytic Leukemia (SM-CMML) by Next Generation Sequencing

BACKGROUND: Systemic mastocytosis (SM) is a heterogenous, clonal mast cell (MC) proliferation, rarely associated with clonal hematologic non-mast cell lineage disease (SM-AHNMD). KIT(D816V) is regarded as driver-mutation in SM-AHNMD. METHODS: DNA isolated from peripheral blood (PB) of an SM-CMML pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rechsteiner, Markus, Müller, Rouven, Reineke, Tanja, Goede, Jeroen, Bohnert, Annette, Zhong, Qing, Manz, Markus G, Moch, Holger, Wild, Peter J, Zimmermann, Dieter R, Tinguely, Marianne
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4100747/ https://www.ncbi.nlm.nih.gov/pubmed/25032071 http://dx.doi.org/10.1186/2162-3619-3-18

Ejemplares similares

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
por: Valent, Peter, et al.
Publicado: (2019)

Prognostic factors and survival in chronic myelomonocytic leukaemia (CMML).
por: Stark, A. N., et al.
Publicado: (1987)

Chronic myelomonocytic leukemia (CMML)-0 with pleural effusion as first manifestation: A case report
por: Hu, Lianbo, et al.
Publicado: (2020)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes
por: Bezerra, Evandro D., et al.
Publicado: (2021)

Systemic mastocytosis associated with chronic myelomonocytic leukemia and xanthogranuloma
por: Tschandl, Philipp, et al.
Publicado: (2012)

Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center
por: Wang, Chao, et al.
Publicado: (2022)

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature
por: Elli, Elena, et al.
Publicado: (2012)

Efficient Induction of Extrinsic Cell Death by Dandelion Root Extract in Human Chronic Myelomonocytic Leukemia (CMML) Cells
por: Ovadje, Pamela, et al.
Publicado: (2012)

SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML
por: Laborde, R R, et al.
Publicado: (2013)

A Case of Synchronous Bone Marrow Chronic Myelomonocytic Leukemia (CMML) and Nodal Marginal Zone Lymphoma (NMZL)
por: Soriano, Paolo K., et al.
Publicado: (2018)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Mouse Models of CMML
por: Belotserkovskaya, Ekaterina, et al.
Publicado: (2021)

Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum
por: Calvo, Xavier, et al.
Publicado: (2022)

P727: REFINING RISK STRATIFICATION IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): A COMPREHENSIVE ASSESSMENT OF THE IPSS-M AND OTHER MOLECULARLY INTEGRATED PROGNOSTIC MODELS
por: Aguirre, Luis E., et al.
Publicado: (2023)

MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
por: Hegemann, Inga, et al.
Publicado: (2020)

Transformation of CMML to AML presenting with acute kidney injury
por: DeBoer, Rebecca, et al.
Publicado: (2020)

Novel recurrent mutations in ethanolamine kinase 1 (ETNK1) gene in systemic mastocytosis with eosinophilia and chronic myelomonocytic leukemia
por: Lasho, T L, et al.
Publicado: (2015)

Skin and bones: systemic mastocytosis and bone
por: Wang, Mawson, et al.
Publicado: (2023)

P536: A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS
por: Dinardo, Courtney, et al.
Publicado: (2023)

Somatic BRCA1 mutations in clinically sporadic breast cancer with medullary histological features
por: Rechsteiner, Markus, et al.
Publicado: (2018)

P691: MULTIOMIC SINGLE-CELL APPROACH REVEALED CLONAL ARCHITECTURE OF KIT MUTATIONS IN CHRONIC MYELOMONOCYTIC LEUKAEMIA PATIENTS WITH/WITHOUT SYSTEMIC MASTOCYTOSIS
por: Wang, Yu-Hung, et al.
Publicado: (2023)

Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF(©)
por: Taylor, Fiona, et al.
Publicado: (2021)

P1365: HUMAN CD117 AS AN IMMUNOTHERAPEUTIC TARGET IN PRECLINICAL MODELS OF ADVANCED SYSTEMIC MASTOCYTOSIS
por: Kaiser, Anne, et al.
Publicado: (2023)

A 27-Year-Old Patient Fulfilling the Diagnostic Criteria of Both CMML and JMML
por: Elghazaly, Assem A., et al.
Publicado: (2016)

Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML
por: Banús-Mulet, Antònia, et al.
Publicado: (2018)

Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
por: Liapis, Konstantinos, et al.
Publicado: (2021)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Extensively drug-resistant Klebsiella pneumoniae ST307 outbreak, north-eastern Germany, June to October 2019
por: Haller, Sebastian, et al.
Publicado: (2019)

Patient‐reported outcomes among patients with systemic mastocytosis in routine clinical practice: Results of the TouchStone SM Patient Survey
por: Mesa, Ruben A., et al.
Publicado: (2022)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition
por: Nucera, Silvia, et al.
Publicado: (2020)

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy
por: Schnegg-Kaufmann, Annatina S., et al.
Publicado: (2023)

VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma
por: Razafinjatovo, Caroline Fanja, et al.
Publicado: (2016)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Cutaneous mastocytosis in childhood
por: Nemat, Katja, et al.
Publicado: (2022)

Avapritinib for Cutaneous Mastocytosis
por: LEE, Hannah, et al.
Publicado: (2021)

Enhanced AGAMOUS expression in the centre of the Arabidopsis flower causes ectopic expression over its outer expression boundaries
por: Cartolano, Maria, et al.
Publicado: (2009)

Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico
por: Jiang, Zeju, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s8ii5n1tvmjv7bd24ic1cdd9ah